This trial was meant to be a phase 1/2, with UTI patients treated in H2 2023.
Instead, as seems to be the trend with Recce, the trial took way longer and ended up only completing the phase 1.
Have a look at the AGM presentation from November. Even then they were claiming to aim to start a phase 3 UTI trial in 2024!
Many of us knew it was ridiculous at the time. I don't know how management thought that giving such a timeline was appropriate.
CR presentation doesn't include sepsis as a target indication anymore, surprise surprise. Yet the company has yet to actually front up honestly about the terrible plasma pharmacokinetics.
They said some of the funds are for new pre-clinical programs. I wonder if they're trying to find a formulation with a longer plasma half-life.
Anyway, bring on the loooooong overdue phase 2 UTI trial!
RCE Price at posting:
49.0¢ Sentiment: None Disclosure: Held
(20min delay)